

Raptor Pharmaceutical Corp  
Form 8-K  
April 16, 2012

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K  
CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): April 12, 2012

RAPTOR PHARMACEUTICAL CORP.

(Exact name of registrant as specified in its charter)

|   |                          |                                      |
|---|--------------------------|--------------------------------------|
| Delaware  | 000-25571                | 86-0883978                           |
| (State or other jurisdiction of<br>incorporation) | (Commission File Number) | (IRS Employer Identification<br>No.) |

9 Commercial Blvd., Suite 200, Novato, California 94949  
(Address of principal executive offices and Zip Code)

Registrant's telephone number, including area code: (415) 382-8111

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))



Item 8.01 Other Events.

On April 12, 2012, the Company issued a press release announcing that the European Patent Office has issued a Notice of Allowance for a key patent covering the use of enteric-coated, delayed-release oral formulations of cysteamine bitartrate, including the Company's proprietary microbead formulation, RP103, as well as other formulations of cystamine and cysteamine. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference into this Item 8.01.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

| Exhibit No. | Exhibit Description   | Filed Here with | Form | Incorporated by Reference |         |             | Filed By |
|-------------|---|-----------------|------|---------------------------|---------|-------------|----------|
|             |   |                 |      | File No.                  | Exhibit | Filing Date |          |
| 99.1        | Press release issued by the Company dated as of April 12, 2012, regarding issuance of Notice of Allowance by European Patent Office | X               |      |                           |         |             |          |

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

RAPTOR PHARMACEUTICAL CORP.

Date: April 13, 2012

By: /s/ Kim R. Tsuchimoto  
Name: Kim R. Tsuchimoto  
Title: Chief Financial Officer, Treasurer and  
Secretary

---

Exhibit Index

| Exhibit No. | Exhibit Description   | Filed Here with | Form | Incorporated by Reference |         |             | Filed By |
|-------------|---|-----------------|------|---------------------------|---------|-------------|----------|
|             |   |                 |      | File No.                  | Exhibit | Filing Date |          |
| 99.1        | Press release issued by the Company dated as of April 12, 2012, regarding issuance of Notice of Allowance by European Patent Office | X               |      |                           |         |             |          |